SIRPA and cancer: IgA antibodies against receptors expressed by cancer cells (Her2, EGFR) could enhance neutrophil-mediated trogocytosis of cancer cells if the CD47-SIRPα innate immune cell checkpoint was simultaneously blocked (26, 27).